The trial will assess adults with recently diagnosed MGMT-unmethylated glioblastoma. Credit: Lightspring / Shutterstock.

The Ivy Brain Tumor Center at Barrow Neurological Institute in the US has announced the dosing of the first subject in the Phase III Gliofocus clinical trial of the PARP1/2 selective inhibitor, niraparib, in adults with recently diagnosed MGMT-unmethylated glioblastoma.

The open-label, randomised trial will assess niraparib’s efficacy against temozolomide, a standard-of-care first-line chemotherapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GSK is supporting the trial, which will involve 450 subjects enrolled at more than 100 clinical sites in 11 countries. 

The Ivy Center’s Phase 0/II trial of niraparib showed positive interim data, leading to the acceleration of the asset to the Phase III study.

In the ongoing early-phase trial, niraparib reached pharmacologically significant concentrations in glioblastoma tumour tissue, surpassing other PARP inhibitors.

See Also:

Treatment with niraparib resulted in a median overall survival of 20.3 months, compared to the historical median of 14 months for a similar population treated with standard care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety profile of the asset was in line with already reported data, without any new safety concerns detected.

Niraparib, an oral, once-daily PARP inhibitor, is currently indicated for first-line maintenance in advanced ovarian cancer.

GSK is evaluating niraparib in several pivotal trials across various tumour types and in combination with other therapies.

Ivy Brain Tumor Center director and Gliofocus study chair Dr Nader Sanai said: “The dosing of the first patient in the pivotal Phase III Gliofocus Study represents a crucial step forward to potentially transform outcomes for MGMT-unmethylated glioblastoma patients worldwide.

“At the Ivy Center, we are committed to pioneering new standards of care that redefine possibilities in brain cancer treatment.”